Alnylam Pharmaceuticals has announced plans to invest US$250 million to expand its manufacturing facility in Norton, Massachusetts, as part of its broader strategy to scale production capacity for RNA‑based therapies. The investment reflects the company’s commitment to strengthening domestic manufacturing infrastructure for next‑generation medicines and meeting growing global demand.
The planned expansion will support the production of lipid nanoparticle (LNP) delivery systems, a critical component used in Alnylam’s portfolio of RNA interference (RNAi) therapeutics. These therapies harness the body’s natural gene‑silencing mechanisms to target diseases at the molecular level, and increasing production capacity is viewed as essential for both current and future programs advancing through clinical development.
Alnylam said the upgraded facility will incorporate advanced automation and quality control technologies to enhance operational efficiency and ensure scalable, high‑quality output. The expansion is also expected to create new jobs in the Norton area, reinforcing the company’s role as a significant local employer and contributor to the regional biotech ecosystem.
The investment aligns with broader trends in the biopharmaceutical sector, where companies are boosting U.S. manufacturing capabilities amid supply chain concerns and rising interest in domestic production of complex biologics and nucleic‑acid based drugs. Alnylam’s move follows similar announcements by other biotech firms that have upgraded or opened facilities to secure production resilience and support long‑term research pipelines.
Alnylam’s leadership said the Norton expansion will position the company to better serve patients worldwide while reinforcing its capacity to innovate and deliver RNAi medicines across multiple therapeutic areas. The company expects facility upgrades to be phased over the next several years, subject to regulatory approvals and construction timelines.
EU warns Africa’s solar riches remain untapped as investment lags
